Recent Updates
Recently added Catalysts
NPCE Positive Sentiment Score: 75/100

NeuroPace to Participate in Upcoming Investor Conferences

Key Takeaway: NeuroPace, Inc. (NPCE) announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. Management, led by CEO Joel Becker and CFO Rebecca Kuhn, will engage in 1x1 meetings and discussions, indicating a proactive approach to investor relations. NeuroPace focuses on transforming the lives of epilepsy patients through its innovative RNS System, which provides personalized and real-time treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple prestigious investor conferences shows strong interest from the investment community.
  • CEO Joel Becker and CFO Rebecca Kuhn are actively engaging with investors, highlighting confidence in the company's direction.
  • The RNS System is a first-in-class solution that could significantly improve patient outcomes.

Full Press Release Details

- Wells Fargo 2023 Healthcare Conference -
- Morgan Stanley 21st Annual Global Healthcare Conference -
- Lake Street Capital Markets 7th Annual Best Ideas Growth Conference -
MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences:
Management will host 1x1 meetings at the Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023, in Everett, MA.
Joel Becker, CEO, and Rebecca Kuhn, CFO, will participate in a fireside chat discussion and host 1x1 meetings at the Morgan Stanley 21st Annual Global Healthcare Conference at 9:30 AM ET on Wednesday, September 13, 2023, in New York, NY.
Management will host 1x1 meetings at the Lake Street Capital Markets 7th Annual Best Ideas Growth Conference on Thursday, September 14, 2023, in New York, NY
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When is NeuroPace participating in the Wells Fargo Conference?

NeuroPace will attend the Wells Fargo 2023 Healthcare Conference on September 7, 2023.

Who will represent NeuroPace at the Morgan Stanley Conference?

Joel Becker, CEO, and Rebecca Kuhn, CFO, will represent NeuroPace.

What is the focus of NeuroPace, Inc.?

NeuroPace focuses on improving treatment for people living with epilepsy.

When are the 1x1 meetings at Lake Street Capital Markets?

1x1 meetings at the Lake Street Capital Markets Conference are on September 14, 2023.

What is the RNS System by NeuroPace?

The RNS System is a brain-responsive device that provides personalized epilepsy treatment.

Last updated: Aug 24, 2023